Skip to content

Targeting the “Undruggable” STAT3 DBD: Free-Energy Perturbation-Guided Design of Covalent Micheliolide Derivatives Targeting Cysteine 367

Sep 2026 · Journal of Chemical Information and Modeling · 0 citations · 65 references

TL;DR

This study establishes C367 as a druggable covalent site in the historically challenging STAT3 DBD, validates FEP-guided optimization of covalent inhibitors, and identifies compound 16 as a promising next-generation lead with a superior drug-like profile for targeting STAT3-dependent cancers.

Abstract

Pancreatic cancer remains a highly lethal malignancy, largely due to persistent STAT3 signaling that sustains cancer stem cells (CSCs) and drives therapeutic resistance. Conventional inhibitors targeting the conserved SH2 domain of STAT3 have exhibited limited selectivity and efficacy. Here, we report that micheliolide (MCL), the active metabolite of the clinical-stage candidate ACT001, inhibits STAT3 through Cys367 (C367)-dependent covalent engagement within the DNA-binding domain (DBD)–a residue unique to STAT3 among STAT family members. This specific modification disrupts STAT3 phosphorylation at Tyr705, nuclear translocation, and transcriptional activity prior to any detectable inhibition of upstream JAK phosphorylation, a finding that suggests that STAT3 inhibition is not primarily driven by upstream kinase blockade. Guided by covalent docking, R-group enumeration, and relative binding free-energy calculations via free-energy perturbation (FEP), we have designed and synthesized a series of MCL analogs. These derivatives retain comparable antiproliferative potency but exhibit markedly improved physicochemical properties, including enhanced kinetic aqueous solubility and optimized lipophilicity. Microscale thermophoresis confirms C367-dependent binding, while microsecond-scale molecular dynamics simulations and pair-interaction energy analyses highlight stable complexes in which electrostatic interactions predominate, with major contributions from key residues (Lys365, Val366, and Ile368). This study establishes C367 as a druggable covalent site in the historically challenging STAT3 DBD, validates FEP-guided optimization of covalent inhibitors, and identifies compound 16 as a promising next-generation lead with a superior drug-like profile for targeting STAT3-dependent cancers. All in all, these findings provide a foundation for advancing selective STAT3 DBD inhibitors toward clinical translation.

View source

Similar papers

Sep 2026

Discovery of novel dual STAT3/TrxR1 inhibitors via pharmacophore fusion as potent lead compounds for colorectal cancer.

Constitutive activation of STAT3 and dysregulation of the thioredoxin reductase 1 (TrxR1) system are deeply implicated in the pathogenesis, progression, and drug resistance of colorectal cancer (CRC). Herein, guided by a pharmacophore fusion strategy, we rationally designed and synthesized a novel series of STAT3/TrxR1...

Yi-Gui Li, Rui Xu, Xin-Hua Xie et al. · 0 citations
Sep 2026

Targeting the nonenzymatic scaffold function of RIPK1 via a VHL-recruiting PROTAC synergizes with immunotherapy in melanoma.

Receptor-interacting protein kinase 1 (RIPK1) mediates cell survival, inflammation, and cell death, and its kinase-independent scaffolding function drives tumor progression and therapeutic resistance, which cannot be eliminated by conventional RIPK1 kinase inhibitors. To overcome this limitation, we adopted proteolysis...

Shun-Xin Guo, Ming-Ze Tang, Pei Yu et al. · 0 citations
Open access Aug 2026

A New Recruitable E3 Ligase UHRF1 Supporting Targeted Protein Degradation: A Minimal Azide as a Recruitment Ligand

The first small-molecule GPX4 degraders that incorporate either electrophilic warheads or a minimal azide group as an E3 recruitment ligand are reported, thereby expanding the E3 ligase toolbox and offering a promising strategy for targeted cancer therapy.

Ze-Hong Lin, Kang Duan, Rui Wan et al. · 0 citations
Sep 2026

Unraveling the allosteric inhibition mechanism of TLR2 by CU-CPT22: A combined DFT and enhanced sampling MD study.

An integrated computational framework is presented that synergistically combines enhanced-sampling molecular dynamics simulations, rigorous binding free energy calculations, and quantum chemical analyses to decipher the mechanistic basis of CU-CPT22 action and establish a robust conceptual and computational framework f...

Peng Jiao, Cheng-Liang Ni, Hao Jin et al. · 0 citations
Aug 2026

Novel VHL ligand-based PROTACs targeting JNK1: design, synthesis, and biological evaluation with potent anti-EMT activity.

This work describes the design, synthesis, and biological evaluation of a series of JNK1-targeting PROTACs that recruit either CRBN or VHL E3 ligases that demonstrates excellent degradation potency and selectivity for JNK1, highlighting its potential as a valuable chemical probe for EMT-associated pathologies.

Shuhua Ren, Ye Zhang, Rui Hao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.